FDA and EMA issue ten joint principles for AI in drug development

FDA's drug and biologics centres and the European Medicines Agency published ten shared 'Guiding Principles of Good AI Practice in Drug Development'. They cover the whole medicine lifecycle, asking for a risk-based approach tied to a defined context of use, data governance, documentation, multidisciplinary development, lifecycle performance monitoring and plain-language communication.